XTL Biopharmaceuticals (XTAE:XTLB) Net Margin %: 284.03% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is XTL Biopharmaceuticals Net Margin %?

XTL Biopharmaceuticals XTAE:XTLB Net Margin % is 284.03% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 943 Biotechnology companies, XTL Biopharmaceuticals ranks worse than 106044.43% on this metric.

Net margin is calculated as Net Income divided by its Revenue. XTL Biopharmaceuticals's Net Income for the six months ended in Dec. 2025 was ₪-4.50 Mil. XTL Biopharmaceuticals's Revenue for the six months ended in Dec. 2025 was ₪-1.58 Mil. Therefore, XTL Biopharmaceuticals's net margin for the quarter that ended in Dec. 2025 was 284.03%.

The historical rank and industry rank for XTL Biopharmaceuticals's Net Margin % or its related term are showing as below:


XTAE:XTLB's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.56
* Ranked among companies with meaningful Net Margin % only.

XTL Biopharmaceuticals  (XTAE:XTLB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

XTL Biopharmaceuticals Net Margin % Related Terms

XTL Biopharmaceuticals Net Margin % Historical Data

* Premium members only.

The historical data trend for XTL Biopharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals Net Margin % Chart

XTL Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XTL Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -1,063.51 284.03

XTAE:XTLB vs VRTX, REGN, RVMD: Net Margin % Comparison

For the Biotechnology subindustry, XTL Biopharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XTL Biopharmaceuticals Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's Net Margin % falls into.


XTL Biopharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

XTL Biopharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-21.346/0
= %

XTL Biopharmaceuticals's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-4.499/-1.584
=284.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 284.03% mean?
XTL Biopharmaceuticals (XTAE:XTLB) has a Net Margin % of 284.03% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on XTL Biopharmaceuticals and its competitors. According to the industry distribution chart, XTL Biopharmaceuticals ranks #999999 out of 943 companies in the Biotechnology industry.
Is XTL Biopharmaceuticals' Net Margin % too high?
XTL Biopharmaceuticals' current Net Margin % is 284.03%. Based on the distribution chart, XTL Biopharmaceuticals ranks #999999 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does XTL Biopharmaceuticals' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XTL Biopharmaceuticals ranks #999999 out of 943 companies for Net Margin %. This places XTL Biopharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on XTL Biopharmaceuticals and its competitors. XTL Biopharmaceuticals's current Net Margin % is 284.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTAE:XTLB) has a current Net Margin % of 284.03%. The current Net Margin % is 284.03%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTAE:XTLB), the current Net Margin % is 284.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XTL Biopharmaceuticals Business Description

Other Exchanges XTLB:USAHHB0:Germany
Address 26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.